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select attributes in order to construct the final list of attributes. This study aims to
test the feasibility of using the nominal group technique (NGT) to select attributes
for DCEs. METHODS: Patients group discussions (4-8 participants) were conducted
in Belgium and the Netherlands to prioritize a list of twelve potentially important
attributes for osteoporosis drug therapy that were retrieved from literature review
and expert discussions. The NGT consisted of three steps: 1) an individual ranking
of the twelve attributes by importance from 1 to 12; 2) a group discussion on each of
the attributes including a group review of the aggregate score of the initial rank-
ings; and 3) a second ranking task of the same attributes. The selection of attributes
for the DCE was based on groups’ ranking and NGT discussions followed by experts’
discussion. RESULTS: In total, 26 osteoporotic patients participated in five nominal
group sessions. Most (80%) patients changed their ranking after the discussion.
However, the average initial and final ranking did not markedly differ, with two
exceptions. In the final rank, the most important medication attributes were effec-
tiveness, side-effects, frequency and mode of administration. It was also observed
that some (15%) patients did not correctly rank from 1 to 12, and the order of
attributes did play a role in the ranking. CONCLUSIONS: The nominal group tech-
nique is feasible and useful for selecting attributes for DCE, although the ranking
task may be cognitively difficult and attributes order should vary over different
NGT sessions.
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OBJECTIVES: To assess the factors that most predicts diabetic patients’ self-effi-
cacy toward osteoporosis with respect to dietary calcium and physical exercise
activity. METHODS: A cross sectional study was undertaken in 250 diabetic type 2
outpatients (T2DM) over a 3-month period in 2011. A pre-validated questionnaire
was administered to assess osteoporosis knowledge tool (OKT-M, two subscale:
exercise and calcium), osteoporosis health behaviour scale (OHBS-M, seven sub-
scales: perceived susceptibility, perceived seriousness, barriers to calcium intake,
barriers to exercise, benefits of calcium intake, benefits of exercise, and health
motivation), osteoporosis risk factor and other demographic questionnaires prior
to the Malaysian osteoporosis self-efficacy scale (OSES-M, two subscale: calcium
and exercise). Then differences, correlations and multiple regressions were exam-
ined in relation to the demographic data, OKT-M and OHBS-M. RESULTS: There
were significant differences in the independent variables: education and income in
relation to OSES-M total scores. Correlations were performed to determine the
relationship between the two dependent variables (OSES-M calcium and exercise
subscale) and the OKT-M and OHBS-M. The OKT-M calcium and exercise subscale,
health motivation and perceived benefits for exercise were positively correlated
with both OSES-M exercise and calcium intake. While perceived benefits for cal-
cium intake was positively correlated with OSES-M exercise only. Perceived barrier
for calcium intake was negatively correlated with self-efficacy for exercise and
calcium. Regression analysis revealed that knowledge, health belief and some de-
mographic data had an impact on OSES-M and the R2scores value were 0.260 and
0.309 for calcium and exercise self-efficacy, respectively. CONCLUSIONS: The pres-
ent study findings suggested that assessing factors affecting the self-efficacy be-
haviour related to bone loss in diabetic patients will raised the potential impor-
tance of these components in the overall understanding of other diabetic
complications and for development of early screening and prevention of osteopo-
rosis in T2DM patients.
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OBJECTIVES: Head to head data from randomized controlled trials (RCTs) compar-
ing biologic monotherapies is limited. Our objective was to compare PROs for to-
cilizumab monotherapy vs. other approved biologic monotherapies, in DMARD-IR
RA patients, based on currently available RCT evidence. METHODS: Full-text pub-
lications of RCTs that assessed tocilizumab, and other biologic therapies, as mono-
therapy in DMARD-IR patients were identified through a systematic literature re-
view. RCTs reporting data on PROs (Health Assessment Questionnaire Disability
Index (HAQ-DI), pain VAS, patient global assessment of disease activity (PGA) VAS,
SF-36, or fatigue) at 24 weeks were included. Where sufficient data was available,
Bayesian network meta-analyses was used to obtain treatment effect estimates
between included interventions. It was assumed that the effects of the aTNF treat-
ments were exchangeable, and data for the assessed aTNFs were pooled to give a
single, more stable estimate. RESULTS: Four studies were identified that formed a
network comparing monotherapy treatments (tocilizumab and aTNFs (adali-
mumab, etanercept, certolizumab pegol)) and reported PRO data. Data on pain VAS,
PGA VAS, and HAQ-DI was most commonly reported. Tocilizumab monotherapy
showed greater improvement in pain [Difference -11.38 (95% CrI -18.40, -4.32)] and
PGA [Difference -10.49 (95% CrI -17.68, -3.24)] compared to the assessed aTNF
monotherapies. Tocilizumab monotherapy showed greater improvement in
HAQ-DI [Difference -0.52 (95% CrI -0.73, -0.31)] compared with placebo, and was at
least as efficacious compared to aTNF monotherapy [Difference -0.16 (95% CrI -0.33,
0.01)]. Insufficient data was reported for the SF-36 and fatigue to allow network
meta-analysis.CONCLUSIONS: Based on network meta-analysis of currently avail-
able RCT evidence, involving indirect comparison of trial findings, tocilizumab
monotherapy was found to have better outcomes than assessed aTNF monothera-
pies in terms of patient reported pain and disease activity in a DMARD-IR RA
population. Tocilizumab was at least as efficacious as aTNF agents in improvement
in physical function.
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OBJECTIVES: To validate and determine the discriminative power of the
FibroDetect®screening tool in helping primary care physicians detect patients with
fibromyalgia in routine practice.METHODS: The FibroDetect included 14 questions
assessing patients’ pain and fatigue, personal history and attitudes, symptoms and
impact on lives. To discriminate between American College of Rheumatology pos-
itive (ACR) patients and ACR negative (ACR-) patients (n276), a scoring method
was created using an iterative process based on statistical and clinical consider-
ations. The discriminant model was then validated with fibromyalgia and non-
fibromyalgia patients (n312). A score threshold for individual ACR classification
was defined. RESULTS:Of the 14 original FibroDetect questions, six questions were
retained in the final scoring, demonstrating discriminative power between ACR
and ACR- patients with an area under the ROC curve of 0.74. A majority of ACR
patients (77%) and less than half of ACR– (39%) had a score  6, suggesting that
patients with such score are likely to be ACR, and should thus be referred to a
fibromyalgia specialist. A total of 8% of ACR patients and 79% of ACR– patients
had a score 3, suggesting that patients with such score were unlikely to be ACR,
and should thus be not be referred to a fibromyalgia specialist. Patients with a
FibroDetect score of 4 or 5 would require further investigation. The predictive ac-
curacy of the tool increased to 0.86 for fibromyalgia and non-fibromyalgia patient
detection. With a 6-point cut-off, the sensitivity was 90% and the specificity was
67% for fibromyalgia and non-fibromyalgia patient detection. CONCLUSIONS: The
FibroDetect is a screening tool that detects potential fibromyalgia patients among
patients with chronic widespread pain. It can be used as a surrogate for ACR clas-
sification criteria in primary care settings, and improve referral to appropriate
specialist.
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OBJECTIVES: Myotonic dystrophy type-1 (DM1) is a dominantly inherited disorder
caused by an unstable CTG repeat expansion on chromosome 19. Clinically the
disease is associated with a wide variety of symptoms. The Myotonic Dystrophy
Health Index (MDHI) is a disease-specific patient reported outcome measure de-
signed to measure total health, and 17 of the most important areas of disease-
specific health in DM1. The items in this instrument were selected utilizing quali-
tative interviews and a cross-sectional study of 278 patients. The MDHI’s total score
(and each of the 17 subscales) are scored from 0-100 with 100 representing the
highest level of disease. The objective of this research is to evaluate the MDHI’s
ability to differentiate between known groups of DM1 patients. METHODS: Each of
the MDHI’s 17 subscales was completed by a group of DM1 patients. DM1 respon-
dents were divided into known groups by employment status, CTG repeat number
(300,300), education (non-college graduate, college graduate), age (21-46,47
years), and duration of symptoms (21,21 years). The average subscale score and
total MDHI score was calculated for each known group. RESULTS: On average, 138
DM1 patients completed each subscale. The MDHI measured a higher disease bur-
den in patients who were unemployed (MDHI total score: 41.5 vs. 25.0), less edu-
cated (41.4 vs. 33.8), had a longer duration of symptoms (41.3 vs. 34.6), were of older
age (38.3 vs. 33.1) and those with a longer CTG repeat number (35.6 vs. 27.6).
CONCLUSIONS: The MDHI and its subscales are capable of differentiating between
known groups of DM1 patients who are suspected of having a higher burden of
disease.
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